



AperTO - Archivio Istituzionale Open Access dell'Università di Torino

Progression and Natural History of Nonalcoholic Fatty Liver Disease in Adults

This is the author's manuscript
Original Citation:
Availability:
This version is available http://hdl.handle.net/2318/1636336 since 2017-05-19T15:37:37Z
Published version:
DOI:10.1016/j.cld.2015.10.010
Terms of use:
Open Access
Anyone can freely access the full text of works made available as "Open Access". Works made available under a Creative Commons license can be used according to the terms and conditions of said license. Use of all other works requires consent of the right holder (author or publisher) if not exempted from copyright protection by the applicable law.

(Article begins on next page)

Progression and Natural History of Nonalcoholic Fatty Liver Disease in Adults

Andrea Marengo, MD, Ramy Ibrahim Kamal Jouness, MD, Elisabetta Bugianesi, MD, PhD*

KEYWORDS

Steatohepatitis • Hepatocellular carcinoma • Type 2 diabetes • Obesity • Cirrhosis

KEY POINTS

- Liver-related mortality is the third cause of death in patients with nonalcoholic fatty liver disease (NAFLD) and is significantly higher in patients with nonalcoholic steatohepatitis (NASH) compared with patients with simple steatosis (7.3% vs 0.9% respectively) within the first 15 years of follow-up.
- The presence and severity of fibrosis on liver biopsy is currently the best indicator of longterm liver outcomes in patients with NAFLD.
- The rate of fibrosis progression is at around 1 stage every 6 to 15 years in patients with NASH but is reduced by half in patients with simple steatosis. However, some patients with NAFLD, also with simple steatosis, can progress rapidly to clinically significant fibrosis.
- Patients with NAFLD with cirrhosis have lower rates of liver-related complications but similar overall mortality as compared with patients with hepatitis C virus because of a higher incidence of cardiovascular events.
- Hepatocellular carcinoma incidence is growing in patients with NAFLD with or without cirrhosis, particularly among those with multiple metabolic risk factors.

INTRODUCTION

The 3 leading causes of death in patients with nonalcoholic fatty liver disease (NAFLD) in descending order are cardiovascular disease, cancer, and liver disease. Although the extrahepatic complications of NAFLD are described elsewhere, this section is focused on the potential liver-related morbidity and mortality that, along with the large prevalence and increasing incidence of this disease in the general population, clearly forecast the future impact of NAFLD on health care.

- 45 The authors have nothing to disclose.
- Division of Gastroenterology and Hepatology, Department of Medical Sciences, A.O. Città della
 - Salute e della Scienza di Torino, University of Turin, Corso Bramante 88, Turin I-10126, Italy * Corresponding author.
- 48 E-mail address: elisabetta.bugianesi@unito.it

Clin Liver Dis ■ (2015) ■-■ http://dx.doi.org/10.1016/j.cld.2015.10.010 1089-3261/15/\$ – see front matter © 2015 Elsevier Inc. All rights reserved.

liver.theclinics.com





ARTICLE IN PRESS

Marengo et al

2

68 69

70

71

49 The burden of data on the liver-related complications of NAFLD comes from studies 50 addressing both the clinical course and the progression of liver damage through 51 paired liver biopsies, but tackling the natural history of NAFLD is one of the most diffi-52 cult challenges for researchers. On one hand, the variety of criteria used to define 53 NAFLD from the clinical point of view (abnormal liver enzymes, hepatic ultrasound, 54 indices of liver fat, and liver biopsy), coupled with the lack of sensitivity and specificity 55 of most of the tests used and the composite nature of NAFLD outcomes, has 56 hampered most clinical studies. On the other hand, studies based on repeat biopsies 57 are limited by sampling variability and by the lack of consensus on what is the best 58 definition of nonalcoholic steatohepatitis (NASH). Several scoring systems have been described to classify liver histology in adults with NAFLD.^{1–3} The NASH Clinical 59 60 Research Network (CRN) classification is the most frequently used in recent studies; 61 however, the NAFLD Activity Score (NAS) has often been used as a surrogate for the 62 diagnosis of NASH, although it is not designed for it but rather for crude evaluation of 63 disease severity, once the diagnosis has been established by the overall pathologic 64 assessment. The prospectively designed Steatosis-Activity-Fibrosis score² has 65 been recently introduced. Despite these caveats, the threat that NAFLD is going to replace chronic hepatitis C as major cause of liver morbidity and mortality should 66 67 be no longer overlooked.

LIVER DISEASE PROGRESSION IN SIMPLE STEATOSIS AND NONALCOHOLIC STEATOHEPATITIS

72 Major prospective cohort studies have been derived from Western populations, 73 whereas data in Asian, African, and Latin American populations are limited 74 (Table 1). The overall long-term mortality of Western patients with the whole spec-75 trum of NAFLD is 34% to 69% higher than the general population of the same age 76 and sex within 15 years of follow-up and is mostly due to cardiovascular disease.⁴ 77 In a community-based study of 420 patients from the United States, liver disease 78 was the third leading cause of death in patients with NAFLD, as compared with the 79 13 leading causes of death in the general Minnesota population.⁵ However, only 21 80 (5%) patients were diagnosed with cirrhosis, and 3.1% developed liver-related com-81 plications, including one requiring liver transplantation (LT) and 2 developing hepato-82 cellular carcinoma (HCC). Higher mortality was associated with age (hazard ratio [HR] 83 per decade 2.2; 95% confidence interval [CI] 1.7-2.7), impaired fasting glucose (HR 84 2.6; 95% CI 1.3-5.2), and cirrhosis (HR 3.1; 95% CI 1.2-7.8).

85 Importantly, there is a prognostic association between the presence of NASH, the 86 stage of liver disease (higher fibrosis stage), and the long-term prognosis of patients 87 with NAFLD. In patients with NASH compared with patients with simple steatosis, 88 both the prevalence of cirrhosis development (10.8% vs 0.7%, respectively) and 89 the liver-related mortality are significantly higher (7.3% vs 0.9%) within the first 90 15 years of follow-up.¹⁰ These findings have been repeatedly confirmed. In a land-91 mark study,⁹ although just 5% of the 129 patients with biopsy-proven NASH enrolled 92 went on to develop end-stage liver disease, including 3 patients with HCC, liver-93 related mortality was increased 10-fold compared with the reference population. 94 However, in patients with simple steatosis (or steatosis with mild inflammation/cellular 95 injury), the overall and liver-related mortality risk was not different. In the long-term 96 follow-up studies available thus far, only 1% of patients with simple steatosis 97 developed cirrhosis and died a liver-related death after a mean 15.6 years of 98 follow-up, compared with 11% of those with NASH having or developing cirrhosis, 99 and 7.3% of those with NASH dying of a liver-related cause after a similar period of


	<u> </u>
000000000000000000000000000000000000000	000
- 0 4 2 0 - 0 - 0 - 0 - 0 - 0 - 0 - 0 - 0 - 0	210

CLD798_proof \blacksquare 3 November 2015 \blacksquare 11:00 am

Author (Year)	Diagnosis	Number	Cirrhosis Prevalence (%)	Follow-up (y)	Main Findings
Teli et al, ⁶ 1995	Bland steatosis	40	0	9.6	There was no progression to NASH/cirrhosis.
Dam-Larsen et al, ⁷ 2004	Bland steatosis	109	1	16.7	Patients with NAFLD have a benign clinical course without excess mortality.
Matteoni et al, ⁸ 1999	NAFLD	98	20	8.3	Poor outcomes are more frequent in patients with NASH.
Adams et al, ⁵ 2005	NAFLD	420	5	7.6	Mortality among patients with NAFLD is higher than the general population.
Ekstedt et al, ⁹ 2006	NAFLD	129	7.8	13.7	NAFLD with elevated ALT/AST is associated with a significant risk of developing end-stage liver disease. Survival is lower in patients with NASH.
Söderberg et al, ¹⁰ 2010	NAFLD	143	9	28.0	Patients with NASH are at increased risk of death compared with the general population.
Lee, ¹¹ 1989	NASH	39	16.3	3.8	NASH has the potential to progress into cirrhosis.
Powell et al, ¹² 1990	NASH	42	7	4.5	NASH should be recognized as a further cause of CC.
Evans et al, ¹³ 2002	NASH	26	4	8.7	There is no evidence of progressive chronic liver injury in patients with NASH.
Hashimoto et al, ¹⁴ 2005	NASH septal fibrosis/cirrhosis	89	48	3.7	The most important consequence of patients with NAFLD with advanced fibrosis was HCC.
Sanyal et al, ¹⁵ 2006	Cirrhotic-stage NASH	152	100	10.0	NASH-cirrhosis has a lower mortality rate compared with HCV- cirrhosis but a greater CV mortality.
Ascha et al, ¹⁶ 2010	Cirrhotic-stage NASH	195	100	3.2	Patients with NASH-cirrhosis have an increased risk of HCC.
Bhala et al, ¹⁷ 2011	NASH septal fibrosis/cirrhosis	247	54	7.4	Patients with NAFLD-cirrhosis have lower rates of liver-related complications and HCC than patients with HCV infection but similar overall mortality.
Stepanova et al, ¹⁸ 2013	NASH	289	NA	12.5	Patients with NASH have a higher risk of liver-related mortality than non-NASH.

Abbreviations: ALT/AST, alanine/aspartate aminotransferase; CC, cryptogenic cirrhosis; CV, cardiovascular; HCC, hepatocellular carcinoma; NA, not available.

follow-up,⁴ leading to the concept that simple steatosis is a relatively "benign state,"
 whereas NASH represents the form of NAFLD potentially progressive to cirrhosis and
 its complications (Fig. 1).



The rate of fibrosis progression in NAFLD is generally slow, and regression may also occur; but a subset of patients either with NASH or simple steatosis can develop severe liver damage quite rapidly (see Fig. 1). In a systematic review and meta-analysis²¹ including 411 patients with biopsy-proven NAFLD (63% with NASH), over 2145.5 person-years of follow-up, 33.6% had fibrosis progression, 43.1% had stable fibrosis, and 22.3% had an improvement in fibrosis stage. The annual fibrosis progression rate in patients with NASH was doubled compared with that in patients with




Fig. 1. Risk stratification for fibrosis progression in NAFLD.

RTICLE IN PRESS

Progression and Natural History of NAFLD in Adults

202 simple steatosis; overall, one stage of fibrosis progression in patients with NASH 203 occurred over 7.1 years in NASH versus 14.3 years in those with simple steatosis. 204 However, the proportion of fibrosis progressors who moved from stage 0 to advanced 205 (stage 3 or 4) fibrosis (rapid progressors) was identical in the 2 histologic subgroups 206 (17% of patients with steatosis and 18% of patients with NASH). Similarly, a recent 207 study has challenged the current concept that simple steatosis is a benign disease 208 and cannot progress to significant liver damage. In a cohort of 108 patients from the United Kingdom with serial biopsies,22 81 had a baseline histologic diagnosis of 209 NASH (75%) and 27 (25%) of NAFLD. The mean annual rate of fibrosis progression 210 211 was 0.08 \pm 0.25 stages. Remarkably, 44% of patients with baseline NAFLD developed NASH, including 10 patients in which fibrosis worsened over time (3 of 10 progressed 212 213 by 1 stage, 5 by 2 stages, and 2 by 3 stages). No difference in the proportion exhibiting 214 fibrosis progression was found between patients with steatosis or NASH at index bi-215 opsy (37% vs 43%), although all patients with steatosis developing fibrosis had also 216 developed NASH on follow-up biopsy (see Fig. 1). Of note, 44% of the patients with 217 steatosis developed NASH after a median 8 years of follow-up, suggesting that 218 NASH usually develops after steatosis. Overall, these data suggest that the necroin-219 flammatory damage per se is not as important as fibrosis for the long-term prognosis or 220 of patients with NAFLD and accordingly the major focus of therapy should be in the 221 resolution of fibrosis rather than of the other histologic features of NASH.

222

223
224
225RISK FACTORS FOR DISEASE PROGRESSION IN SIMPLE STEATOSIS AND
NONALCOHOLIC STEATOHEPATITIS

226 Provided that the presence and severity of fibrosis is the key factor determining long-227 term, liver-related mortality, the key question is which are the main determinants of 228 NAFLD progression that can be identified without a liver biopsy. Age, body mass in-229 dex (BMI), type 2 diabetes mellitus (T2DM) or metabolic syndrome (MetS), and insulin 230 resistance assessed by homeostasis model assessment are well-recognized risk fac-231 tors for advanced fibrosis in multiple cross-sectional studies; but few of them have 232 also been examined in longitudinal studies and in relation to their ability to predict 233 the progression of NAFLD. In the previously cited meta-analysis,²¹ the presence of 234 hypertension (odds ratio [OR] 1.94; 95% CI 1.00-3.74) and a low aspartate amino-235 transferase (AST)/alanine transaminase (ALT) ratio at the time of baseline biopsy 236 was associated with the progression of fibrosis, whereas in the most recent study,²² 237 most (80%) of the patients with NAFLD in which fibrosis worsened were diabetic and 238 had a longer disease duration. Fibrosis progressors had also a significantly lower 239 platelet count (P = .04) and higher AST/ALT ratio (P = .04) and Fibrosis 4 (FIB-4) 240 score (P = .02) than nonprogressors. The same study identified the FIB-4 score as 241 the only significant baseline factor able to predict fibrosis progression, whereas the 242 presence of T2DM (OR 6.25; CI 1.88-20) and FIB-4 score (OR 3.1; CI 1.4-6.8, 243 P = .004) at the time of follow-up liver biopsy were indicators of the presence of 244 fibrosis.

245 Among genetic factors, homozygosity for the patatin-like phospholipase domain-246 containing protein (PNPLA3) 148M allele has been associated with a 3.3-fold 247 increased risk of both NASH and liver fibrosis independent of BMI, T2DM, and stea-248 tosis (for NASH) and age, BMI, T2DM, steatosis, and NASH (for fibrosis).²³ The as-249 sociation between PNPLA3 I148M and the severity of fibrosis in NAFLD has been 250 almost contemporarily replicated by independent groups in adults^{24,25} and in the 251 pediatric population²⁶ and confirmed by a recent meta-analysis.²⁷ Studies on the 252 ability of genetic and other factors to predict the risk of disease progression are





6

256

296

297

definitely needed, not only in the Western population but also in other developed
 and developing countries where the risk of NAFLD is paralleling the economic
 development.

257LIVER DISEASE PROGRESSION IN NONALCOHOLIC STEATOHEPATITIS-RELATED258CIRRHOSIS

It is well established that patients with severe liver damage are more likely to develop
liver-related complications, and pooled data from long-term (~10 years) follow-up
studies of patients with NAFLD with advanced fibrosis and cirrhosis demonstrate a
16% mortality with 60% of the deaths liver-related compared with only approximately
9% liver-related in long-term (~15 years) follow-up studies of patients with NAFLD
without advanced fibrosis or cirrhosis.⁴ However, the natural history of cirrhosis due
to NASH has been addressed by only few studies.

In an Australian study of 23 patients with NASH cirrhosis identified from a hospital 267 database, the 10-year survival rate was 84%. Comparing these patients to subjects 268 affected by hepatitis C virus (HCV)-related cirrhosis, the study showed no difference 269 between liver-related deaths or all-cause mortality between the two groups after 270 adjustment for baseline differences, despite a trend toward improved survival in 271 NASH.²⁸ In a larger study,¹⁵ the 10-year survival in the NASH group was 80.9%, 272 significantly better than in the HCV controls of similar age, sex, and Child-Pugh score, 273 principally because of a lower risk of hepatic decompensation in the NASH cohort. In 274 subjects with NASH-related cirrhosis, ascites was the first and most common clinical 275 feature of decompensation but occurred at a slower rate than in patients with HCV. 276 Once ascites developed, the rate of hepatorenal syndrome was similar in the two 277 groups. Development of varices and the rates of variceal hemorrhage were similar 278 in NASH-related and HCV-related cirrhosis, whereas the incidence of hepatic en-279 cephalopathy was intermediate between that for ascites and variceal hemorrhage. 280 Remarkably, subjects with NASH-related cirrhosis had a significantly higher rate of 281 cardiovascular mortality compared with HCV-related cirrhosis. These data have 282 been corroborated in another independent cohort.¹⁶ In a multicenter prospective 283 study,¹⁷ the long-term morbidity and mortality of 247 patients with NAFLD advanced 284 fibrosis or cirrhosis was compared with 264 patients with HCV cirrhosis. Both cohorts 285 were Child-Pugh class A and had cirrhosis confirmed by liver biopsy. In the NAFLD 286 cohort, liver-related complications occurred in 19.4% of cases and deaths or LT in 287 13.4%, compared with 16.7% and 9.4%, respectively, in the HCV cohort. When 288 adjusting for baseline differences in age and sex, the cumulative incidence of liver-289 related complications was lower in the NAFLD than the HCV cohort, including inci-290 dent HCC; but cardiovascular events and overall mortality were similar in both 291 groups. Thus, NAFLD seems to have lower rates of liver-related complications but 292 a similar overall mortality compared with patients with HCV. Fibrosis stage and stan-293 dard clinical and biochemical parameters are relevant in assessing the risk of future 294 liver complications. 295

HEPATOCELLULAR CARCINOMA IN NONALCOHOLIC FATTY LIVER DISEASE

The exact burden of HCC related to NAFLD remains uncertain, but it is clear that NAFLD is going to be the most common underlying etiologic risk factor for HCC. In a population-based study in the United States, NAFLD accounted for 59% of HCC cases, with a cumulative incidence of 0.3% over a 6-year follow-up.²⁹ The mortality rates for HCC ranged from 0.25% to 2.3% over 8.3 and 13.7 years of follow-up in 2 further studies.^{8,9} In the largest prospective community-based study performed so

Progression and Natural History of NAFLD in Adults

far,³⁰ after a mean follow-up of 7.6 years, only 0.5% patients developed HCC; but the rate among cirrhotic patients was 10%. As expected, the risk of HCC is more elevated when examining patients with advanced liver disease; but patients with NAFLD with HCC have a lower prevalence of cirrhosis than patients with HCC in HCV-related and other liver diseases. This prevalence is an important characteristic of HCC in NAFLD, which has been reported in multiple publications (Table 2).



310 311 Hepatocellular Carcinoma in Nonalcoholic Steatohepatitis–Related Cirrhosis

312 Two longitudinal studies on the natural history of NASH-related cirrhosis in the United 313 States¹⁵ and Japan³⁰ confirmed that HCC was the cause of 47% of deaths in patients 314 with NASH, representing an independent risk factor for liver-related mortality (HR 315 7.96). Overall, the relative HCC risk and mortality rate in NASH-related cirrhosis seems 316 to be lower in comparison with viral or alcohol-related cirrhosis. In a large cohort 317 study, HCC was significantly more common in HCV than NAFLD (6.8% vs 2.4%, 318 respectively)¹⁷ and the HCV cohort had an approximate 0.15% risk per year of HCC 319 development versus 0.05% in NAFLD. However, the perception that HCC is a rare 320 and late complication of NAFLD has been denied by recent reports. In North East 321 England, the overall incidence of HCC increased 1.8-fold from 2000 to 2010; but 322 most shocking was a more than 10-fold increase in HCC associated with NAFLD, ac-323 counting for 34.8% of all the cases in 2010 and making it the single most common un-324 derlying cause.³⁹ Not surprisingly, this increasing incidence of HCC was associated 325 with an increasing prevalence of overweight and obesity (61.0% in 2000 and 65.5% 326 in 2010). This finding confirms that the apparently lower rates of HCC arising in 327 NAFLD-cirrhosis compared with other causes of chronic liver disease are definitely 328 outweighed by the much larger spread of NAFLD in the general population and 329 open future scenarios in the approach to HCC.

Hepatocellular Carcinoma in Patients with Nonalcoholic Fatty Liver Disease Without Cirrhosis

333 The most worrisome issue consistently emerging in the last years is the onset of 334 HCC in patients with NAFLD who do not have cirrhosis yet. A French study analyzed 335 a cohort of 31 patients with HCC with MetS as the only risk factor for liver disease 336 and found mild or no fibrosis in most cases, compared with those harboring HCC 337 associated with an overt cause of liver disease (65% vs 26%, P<.0001).38 338 The absence of cirrhosis was further confirmed in 38% of Japanese patients⁴¹ 339 and in one-third of patients from North East England with NAFLD-related HCC.⁴¹ 340 As patients without cirrhosis are not in surveillance programs, most (62.3%) pre-341 sented symptomatically with larger tumors, and their median survival was just 342 7.2 months.³⁹

In conclusion, HCC in NAFLD should not be underestimated for several reasons.
First, once cirrhosis had developed, HCC represents a frequent complication, with
an incidence of up to 10% over a 7-year follow-up. Secondly, HCC can also arise in
the absence of cirrhosis in patients with NASH with multiple metabolic risk factors,
mainly obesity and T2DM. These observations arouse an urgent need to better understand the risk factors linked to the development of HCC, especially in noncirrhotic
livers, and to update screening programs.

350

351 Nonalcoholic Fatty Liver Disease in Lean Patients

A small but significant proportion of patients (7%–21%) develops NAFLD despite normal BMI, and they are defined as lean or normal weight NAFLD.^{42–46} They are generally described in the Asian populations; but within the National Health and

		<u>, , , , , , , , , , , , , , , , , , , </u>
υ ο Γ ∞ 0 - 1 0 ω 4 υ	× 2 0 − 0 ω 4 λ δ Γ × 2 0 − 0 ω 4	8 7 6 5 4 3 2 1 0 9 8 7 6 5 4 3 2 1 0 9 8 7 6 5

Author (Year)	Diagnosis	Study Population	Main Findings
Bugianesi et al, ³¹ 2002	Cirrhosis	641 patients with cirrhosis-associated HCC	NAFLD-related features are more frequent in HCC arising in CC than viral or alcoholic cirrhosis.
Marrero et al, ³² 2002	Cirrhosis	105 patients with HCC	CC-related HCC was less likely to have undergone HCC surveillance and had larger tumors at diagnosis.
Regimbeau et al, ³³ 2004	Cirrhosis	210 patients who underwent resection for HCC	Obesity and T2DM may be important risk factors for HCC, via NAFLD and CC.
Ascha et al, ¹⁶ 2010	Cirrhosis	510 patients with cirrhosis	Patients with NASH cirrhosis have an increased risk of HCC yearly cumulative incidence (2.6% vs 4.0% in HCV).
Yasui et al, ³⁴ 2011	Cirrhosis and NAFLD/NASH	87 HCC cases; no cirrhosis in 43 patients	Most patients with NASH who develop HCC are men with features of MetS and at a less advanced stage of liver fibrosis.
Mittal et al, ³⁵ 2015	Cirrhosis	1500 patients with HCC	NAFLD is the third most common risk factor for HCC. Cirrhosis was less common in NAFLD-related cases compared with alcoholic or HCV-related HCC.
Wong et al, ³⁶ 2014	Cirrhosis	10,061 adult LT recipients for HCC	NAFLD is the most rapidly growing indication for LT in HCC cases in the United States.
Tateishi et al, ³⁷ 2015	Cirrhosis	33,782 patients with HCC (596 NAFLD related)	Most cases of nonviral HCC are related to lifestyle factors, including obesity and T2DM.
Paradis et al, ³⁸ 2009	NAFLD/NASH	31 patients with HCC with MetS as the only risk factor for liver disease	NAFLD contributes to noncirrhotic HCC.
Dyson et al, ³⁹ 2014	Cirrhosis and NAFLD/NASH	623 patients with HCC	HCC cases without cirrhosis most commonly occurred in NAFLD. Patients without cirrhosis were not in surveillance programs, and most presented symptomatically with larger tumors.
Leung et al, ⁴⁰ 2015	Cirrhosis and NAFLD/NASH	54 patients with NAFLD-associated HCC	HCC can develop in NAFLD without cirrhosis. At diagnosis, such tumors are larger than those in cirrhotic patients.

Abbreviation: CC, cryptogenic cirrhosis.

ARTICLE IN PRESS

Progression and Natural History of NAFLD in Adults

406 Nutrition Examination Survey III cohort, 7.4% of subjects had a normal BMI (<25 kg/ 407 m²).⁴⁷ Lean individuals with NAFLD constitute a subgroup of patients relatively free 408 from MetS, although insulin resistance can be increased anyway compared with 409 healthy controls.⁴⁸ The common variant in the PNPLA3 gene (I148M) can partially 410 explain the onset of NAFLD in lean patients; but in a recent study,⁴⁶ PNPLA3 polymor-411 phism did not contribute to incident NAFLD.

412 The pivotal question is whether lean patients with NAFLD have a different disease 413 progression compared with obese patients with NAFLD, but the answer is still 414 unknown because of the paucity of clinical and histologic outcome data. In a 415 biopsy series, leaner Asian patients with NASH were less likely to have advanced fibrosis and cirrhosis than Caucasians.⁴⁹ However, the preliminary report of an in-416 417 ternational study indicated a more severe prognosis in lean subjects with biopsyproven NAFLD compared with overweight/obese subjects.⁵⁰ In a cohort of 1090 418 419 NAFLD cases, only 125 (11.5%) were classified as lean at first diagnosis. In accordance with previous studies, lean patients with NAFLD were characterized by a 420 421 lower prevalence of T2DM, hypertension, hypertriglyceridemia, low high-density li-422 poproteins cholesterol, central obesity, and MetS as well as more frequently normal 423 liver enzymes and a lower prevalence or severity of insulin resistance. Histology 424 was characterized by milder degrees of steatosis and fibrosis but more severe 425 lobular inflammation. In a subgroup of 483 patients, whereby the index liver biopsy 426 had been performed before 2005, the difference in overall mortality between the 427 lean and nonlean NAFLD group was analyzed. Over a follow-up of 11 years, 71 428 of the 483 (14.7%) patients died; surprisingly, the cumulative survival was signifi-429 cantly shorter in lean patients with NAFLD as compared with non-lean NAFLD 430 (log-rank test = 5.6; P<.02). This difference remained significant when adjusted 431 in a Cox regression model, with only lean NAFLD (HR 11.8; 95% CI 2.8-50.1; 432 P = .001) and age (HR 1.05; 95% CI 1.008–1.1; P = .02) identified as prognostic factors. These provocative data point out that the definition of risk factors for the 433 434 progression of NAFLD is still an open issue and that we should not quickly 435 discharge lean patients with NAFLD from the gastroenterology outpatients clinic, 436 overlooking their potential liver-related complications.

437

438 439 SUMMARY

440 Patients with NAFLD are at risk of liver-related complications and death; but fibrosis 441 progression is generally slow, taking around 8 years to progress from stage 0 to 442 stage 1 fibrosis, although there is a subgroup of rapid progressors who can prog-443 ress 3 to 4 stages within 2 to 6 years. There is a prognostic association between 444 the histologic stage of liver disease and the long-term prognosis of patients with 445 NAFLD. Currently the presence and severity of fibrosis at index biopsy is the best 446 indicator of the long-term liver outcome. Pooled data from long-term follow-up 447 studies of NAFLD demonstrate only approximately 9% of liver-related deaths in pa-448 tients without advanced fibrosis or cirrhosis, whereas patients with NAFLD with 449 advanced fibrosis and cirrhosis demonstrate a 16% mortality with 60% of the 450 deaths liver related. Among nonhistologic predictors, hypertension and T2DM at 451 presentation are the factors most consistently associated with the risk of disease 452 progression that is observed also in lean patients. HCC is a worrisome growing 453 complication of NAFLD at any stage. Scientific advances in the understanding of 454 mechanisms of fibrosis and carcinogenesis in NAFLD are awaited with interest in 455 order to provide clinical indexes to predict and prevent the risk of liver-related 456 deaths.



457 **REFERENCES**

458

459

460

466

467

468

469

470

471

472

473

474

475

476

477

478

479

480

481

482

486

487

488

489

- Kleiner DE, Brunt EM, Van Natta M, et al. Design and validation of a histological scoring system for non-alcoholic fatty liver disease. Hepatology 2005;41: 1313–21.
- 461
 462
 463
 464
 465
 464
 465
 464
 465
 464
 465
 464
 465
 464
 465
 464
 465
 464
 465
 464
 465
 464
 465
 464
 465
 464
 465
 464
 465
 464
 465
 464
 465
 465
 464
 465
 464
 465
 464
 465
 465
 465
 465
 465
 466
 467
 467
 468
 469
 469
 469
 469
 469
 460
 460
 460
 460
 460
 460
 461
 462
 463
 464
 464
 465
 464
 465
 464
 465
 464
 465
 465
 464
 465
 465
 464
 465
 465
 464
 465
 465
 464
 465
 464
 465
 464
 465
 464
 465
 464
 465
 464
 465
 465
 464
 465
 465
 465
 464
 465
 464
 465
 465
 465
 465
 466
 467
 467
 467
 468
 468
 468
 468
 468
 468
 468
 468
 468
 468
 468
 468
 468
 469
 469
 469
 469
 469
 469
 469
 469
 469
 469
 469
 469
 469
 469
 469
 469
 469
 469
 469
 469
 469
 469
 469
 469
 469
 469
 469
 469
 469
 469
 469
 469
 469
 469
 469
 - Brunt EM, Kleiner DE, Wilson LA, et al. Nonalcoholic fatty liver disease (NAFLD) activity score and the histopathologic diagnosis in NAFLD: distinct clinicopathologic meanings. Hepatology 2011;53:810–20.
 - Angulo P. The natural history of NAFLD. In: Farrell GC, McCullough AJ, Day CP, editors. Non-alcoholic fatty liver disease: a practical guide. London: Wiley Blackwell Press; 2013. p. 37–45.
 - 5. Adams LA, Lymp JF, St Sauver J, et al. The natural history of nonalcoholic fatty liver disease: a population-based cohort study. Gastroenterology 2005;129:113–21.
 - 6. Teli MR, James OF, Burt AD, et al. The natural history of nonalcoholic fatty liver: a follow-up study. Hepatology 1995;22:1714–9.
 - 7. Dam-Larsen S, Franzmann M, Andersen IB, et al. Long term prognosis of fatty liver: risk of chronic liver disease and death. Gut 2004;53:750–5.
 - 8. Matteoni CA, Younossi ZM, Gramlich T, et al. Nonalcoholic fatty liver disease: a spectrum of clinical and pathological severity. Gastroenterology 1999;116:1413–9.
 - 9. Ekstedt M, Franzen LE, Mathiesen UL, et al. Long-term follow-up of patients with NAFLD and elevated liver enzymes. Hepatology 2006;44:865–73.
 - 10. Söderberg C, Stål P, Askling J, et al. Decreased survival of subjects with elevated liver function tests during a 28-year follow-up. Hepatology 2010;51:595–602.
- 11. Lee RG. Nonalcoholic steatohepatitis: a study of 49 patients. Hum Pathol 1989; 20:594–8.
 - Powell EE, Cooksley WG, Hanson R, et al. The natural history of nonalcoholic steatohepatitis: a follow-up study of forty-two patients for up to 21 years. Hepatology 1990;11:74–80.
 - 13. Evans CD, Oien KA, MacSween RN, et al. Non-alcoholic steatohepatitis: a common cause of progressive chronic liver injury? J Clin Pathol 2002;55:689–92.
- 490
 491
 491
 492
 493
 494
 494
 494
 495
 494
 495
 496
 496
 497
 497
 498
 498
 498
 498
 498
 498
 498
 498
 498
 498
 498
 498
 499
 499
 490
 490
 491
 491
 491
 491
 491
 491
 491
 491
 492
 491
 491
 491
 492
 493
 494
 494
 494
 494
 494
 494
 494
 496
 497
 498
 498
 498
 498
 498
 498
 498
 498
 498
 498
 498
 498
 498
 498
 498
 498
 498
 498
 498
 498
 498
 498
 498
 498
 498
 498
 498
 498
 498
 498
 498
 498
 498
 498
 498
 498
 498
 498
 498
 498
 498
 498
 498
 498
 498
 498
 498
 498
 498
 498
 498
 498
 498
 498
 498
 498
 498
 498
 498
 498
 498
 498
 498
 498
 498
 498
 498
 498
 498
 498
 498
 498
 498
 498
 498
 498
 498
 498
 498
 498
 498
 498
 498
 498
 498
 498
 498
 498
 498
 498
 498
 498
 498
 498
 498
 498
 498
 498
 498
 498
 498
 498
 498
- 492
 493
 493
 494
 494
 495
 495
 494
 495
 494
 495
 494
 495
 494
 494
 495
 495
 494
 494
 494
 495
 495
 494
 494
 494
 495
 495
 495
 494
 494
 494
 495
 495
 494
 494
 494
 494
 494
 494
 494
 494
 494
 494
 494
 494
 494
 494
 494
 494
 494
 494
 494
 494
 494
 494
 494
 494
 494
 494
 494
 494
 494
 494
 494
 494
 494
 494
 494
 494
 494
 494
 494
 494
 494
 494
 494
 494
 494
 494
 494
 494
 494
 494
 494
 494
 494
 494
 494
 494
 494
 494
 494
 494
 494
 494
 494
 494
 494
 494
 494
 494
 494
 494
 494
 494
 494
 494
 494
 494
 494
 494
 494
 494
 494
 494
 494
 494
 494
 494
 494
 494
 494
 494
 494
 494
 494
 494
 494
 494
 494
 494
 494
 494
 494
 494
 494
 494
 494
 494
 494
 494
 494
 494
 494
 494
 494
 494
 494
 494
 494
 494
 494
 494
 494
 494
 494
 494
- 16. Ascha MS, Hanouneh IA, Lopez R, et al. The incidence and risk factors of hepatocellular carcinoma in patients with nonalcoholic steatohepatitis. Hepatology 2010;51:1972–8.
- 17. Bhala N, Angulo P, van der Poorten D, et al. The natural history of nonalcoholic fatty liver disease with advanced fibrosis or cirrhosis: an international collaborative study. Hepatology 2011;54:1208–16.
- 18. Stepanova M, Rafiq N, Makhlouf H, et al. Predictors of all-cause mortality and liver-related mortality in patients with non-alcoholic fatty liver disease (NAFLD). Dig Dis Sci 2013;58:3017–23.
- 19. Younossi ZM, Stepanova M, Rafiq N, et al. Pathologic criteria for nonalcoholic steatohepatitis: interprotocol agreement and ability to predict liver-related mortal-ity. Hepatology 2011;53:1874–82.

ARTICLE IN PRESS

Progression and Natural History of NAFLD in Adults

- Angulo P, Bugianesi E, Bjornsson ES, et al. Simple noninvasive systems predict
 long-term outcomes of patients with nonalcoholic fatty liver disease. Gastroenter ology 2013;145:782–9.
- 511 21. Singh S, Allen AM, Wang Z, et al. Fibrosis progression in nonalcoholic fatty liver
 512 vs nonalcoholic steatohepatitis: a systematic review and meta-analysis of paired513 biopsy studies. Clin Gastroenterol Hepatol 2015;13:643–54.
- 514 22. McPherson S, Hardy T, Henderson E, et al. Evidence of NAFLD progression from
 515 steatosis to fibrosing-steatohepatitis using paired biopsies: Implications for prog 516 nosis and clinical management. J Hepatol 2015;62:1148–55.
- 517 23. Valenti L, Al-Serri A, Daly AK, et al. Homozygosity for the patatin-like phospholi518 pase-3/adiponutrin 1148M polymorphism influences liver fibrosis in patients with
 519 nonalcoholic fatty liver disease. Hepatology 2010;51:1209–17.
- Rotman Y, Koh C, Zmuda JM, et al. The association of genetic variability in patatinlike phospholipase domain-containing protein 3 (PNPLA3) with histological
 severity of nonalcoholic fatty liver disease. Hepatology 2010;52:894–903.
- 523 25. Speliotes EK, Butler JL, Palmer CD, et al. PNPLA3 variants specifically confer
 524 increased risk for histologic nonalcoholic fatty liver disease but not metabolic dis 525 ease. Hepatology 2010;52:904–12.
- 526 26. Valenti L, Alisi A, Galmozzi E, et al. 1148M patatinlike phospholipase domain527 containing 3 gene variant and severity of pediatric nonalcoholic fatty liver disease.
 528 Hepatology 2010;52:1274–80.
- 529 27. Sookoian S, Pirola CJ. Meta-analysis of the influence of 1148M variant of patatin-like
 530 phospholipase domain containing 3 gene (PNPLA3) on the susceptibility and histo 531 logical severity of nonalcoholic fatty liver disease. Hepatology 2011;53:1883–94.
- 48. Hui JM, Kench JG, Chitturi S, et al. Long-term outcomes of cirrhosis in nonalco holic steatohepatitis compared with hepatitis C. Hepatology 2003;38:420–7.
- Sanyal A, Poklepovic A, Moyneur E, et al. Population-based risk factors and
 resource utilization for HCC: US perspective. Curr Med Res Opin 2010;26:2183–91.
- 536 30. Yatsuji S, Hashimoto E, Tobari M, et al. Clinical features and outcomes of cirrhosis
 537 due to non-alcoholic steatohepatitis compared with cirrhosis caused by chronic
 538 hepatitis C. J Gastroenterol Hepatol 2009;24:248–54.
- 539 31. Bugianesi E, Leone N, Vanni E, et al. Expanding the natural history of nonalco540 holic steatohepatitis: from cryptogenic cirrhosis to hepatocellular carcinoma.
 541 Gastroenterology 2002;123:134–40.
- 542 32. Marrero JA, Fontana RJ, Su GL, et al. NAFLD may be a common underlying liver
 543 disease in patients with hepatocellular carcinoma in the United States. Hepatol544 ogy 2002;36:1349–54.
- 545 33. Regimbeau JM, Colombat M, Mognol P, et al. Obesity and diabetes as a risk
 546 factor for hepatocellular carcinoma. Liver Transpl 2004;10:S69–73.
- 547 34. Yasui K, Hashimoto E, Komorizono Y, et al. Characteristics of patients with nonal548 coholic steatohepatitis who develop hepatocellular carcinoma. Clin Gastroenterol
 549 Hepatol 2011;9:428–33.
- Mittal S, Sada YH, El-Serag HB, et al. Temporal trends of nonalcoholic fatty liver
 disease-related hepatocellular carcinoma in the veteran affairs population. Clin
 Gastroenterol Hepatol 2015;13:594–601.
- 36. Wong RJ, Cheung R, Ahmed A. Nonalcoholic steatohepatitis is the most rapidly
 growing indication for liver transplantation in patient with hepatocellular carcinoma
 in the U.S. Hepatology 2014;59:2188–95.
- Tateishi R, Okanoue T, Fujiwara N, et al. Clinical characteristics, treatment, and
 prognosis of non-B, non-C hepatocellular carcinoma: a large retrospective multi center cohort study. J Gastroenterol 2015;50:350–60.



Marengo et al

- 559 38. Paradis V, Zalinski S, Chelbi E, et al. Hepatocellular carcinomas in patients with 560 metabolic syndrome often develop without significant liver fibrosis: a pathological 561 analysis. Hepatology 2009;49:851-9. 562
 - 39. Dyson J, Jaques B, Chattopadyhay D, et al. Hepatocellular cancer: the impact of obesity. type 2 diabetes and multidisciplinary team. J Hepatol 2014;60:110-7.
 - 40. Leung C, Yeoh SW, Patrick D, et al. Characteristics of hepatocellular carcinoma in cirrhotic and non-cirrhotic non-alcoholic fatty liver disease. World J Gastroenterol 2015;21:1189-96.
 - 41. Tokushige K, Hashimoto E, Horie Y, et al. Hepatocellular carcinoma in Japanese patients with nonalcoholic fatty liver disease, alcoholic liver disease, and chronic liver disease of unknown etiology: report of the nationwide survey. J Gastroenterol 2011;46:1230-7.
 - 42. Wong VW, Chu WC, Wong GL, et al. Prevalence of non-alcoholic fatty liver disease and advanced fibrosis in Hong Kong Chinese: a population study using protonmagnetic resonance spectroscopy and transient elastography. Gut 2012;61: 409-15.
 - 43. Das K, Das K, Mukherjee PS, et al. Nonobese population in a developing country has a high prevalence of nonalcoholic fatty liver and significant liver disease. Hepatology 2010;51:1593-602.
 - 44. Kwon YM, Oh SW, Hwang SS, et al. Association of nonalcoholic fatty liver disease with components of metabolic syndrome according to body mass index in Korean adults. Am J Gastroenterol 2012;107:1852-8.
 - 45. Liu CJ. Prevalence and risk factors for non-alcoholic fatty liver disease in Asian people who are not obese. J Gastroenterol Hepatol 2012;27:1555-60.
 - 46. Wong VW, Wong GL, Yeung DK, et al. Incidence of non-alcoholic fatty liver disease in Hong Kong: a population study with paired proton-magnetic resonance spectroscopy. J Hepatol 2015;62:182-9.
 - 47. Younossi ZM, Stepanova M, Negro F, et al. Nonalcoholic fatty liver disease in lean individuals in the United States. Medicine 2012;91:319-27.
- 48. Vos B, Moreno C, Nagy N, et al. Lean nonalcoholic fatty liver disease (Lean-NAFLD): 592 a major cause of cryptogenic liver disease. Acta Gastroenterol Belg 2011;74: 593 389-94. 594
 - 49. Wong VW, Vergniol J, Wong GL, et al. Diagnosis of fibrosis and cirrhosis using liver stiffness measurement in nonalcoholic fatty liver disease. Hepatology 2010;51:454-62.
- 597 50. Dela Cruz AC, Bugianesi E, George J, et al. Characteristics and long-term prognosis 598 of lean patients with non-alcoholic fatty liver disease. Gastroenterology 2014;146: 599 S-909.

CLD798 proof ■ 3 November 2015 ■ 11:00 am

12

563

564

565

566

567

568

569 570

571

572

573

574

575

576

577

578

579

580

581 582

583

584

585

586

587

588

589

590

591

595

596

AUTHOR QUERY FORM

	Journal: CLD	
ELSEVIER	Article Number: 798	

Dear Author,

Please check your proof carefully and mark all corrections at the appropriate place in the proof (e.g., by using on-screen annotation in the PDF file) or compile them in a separate list. Note: if you opt to annotate the file with software other than Adobe Reader then please also highlight the appropriate place in the PDF file. To ensure fast publication of your paper please return your corrections within 48 hours.

For correction or revision of any artwork, please consult http://www.elsevier.com/artworkinstructions.

Any queries or remarks that have arisen during the processing of your manuscript are listed below and highlighted by flags in the proof.

Location in article	Query / Remark: Click on the Q link to find the query's location in text Please insert your reply or correction at the corresponding line in the proof
Q1	Please approve the short title to be used in the running head at the top of each right-hand page.
Q2	Are author names and order of authors OK as set?
Q3	This is how your name will appear on the contributor's list. Please add your academic title and any other necessary titles and professional affiliations, verify the information, and OK ANDREA MARENGO, MD , Division of Gastroenterology and Hepatology, Department of Medical Sciences, A.O. Città della Salute e della Scienza di Torino, University of Turin, Turin, Italy RAMY IBRAHIM KAMAL JOUNESS, MD , Division of Gastroenterology and Hepatology, Department of Medical Sciences, A.O. Città della Salute e della Scienza di Torino, University of Turin, Turin, Italy ELISABETTA BUGIANESI, MD, PhD , Division of Gastroenterology and Hepatology, Department of Medical Sciences, A.O. Città della Salute e della Scienza di Torino, University of Turin, Turin, Italy
Q4	The following synopsis is the one that you supplied but edited down to less than 100 words. Please confirm OK or submit a replacement (also less than 100 words). Please note that the synopsis will appear in PubMed: Liver-related mortality is the third cause of death in patients with nonalcoholic fatty liver disease, but the long-term prognosis basically depends on the presence and severity of liver damage. Thus, life expectancy in patients with simple steatosis is not different from the general population, but liver-related mortality is significantly higher in patients with nonalcoholic steatohepatitis (NASH), particularly in those with advanced fibrosis. Progression of liver disease is observed in up to one-third of patients with NASH. The long-term hepatic prognosis mostly depends on the histologic stage at initial liver biopsy, but multiple risk factors may concur.
Q5	Please verify the affiliation address.
Q6	As per the editorial remarks, "Per Clinics style only 3–5 key points are allowed. Hence the sixth key point list has been deleted." Please verify.
Q7	Please check the article throughout to be sure the edits preserve your intent.

Q8	If there are any drug dosages in your article, please verify them and indicate that you have done so by initialing this query.
Q 9	Please verify that the hierarchy of the heading levels are OK as set.
Q10	Please clarify whether the quote "benign state" is a direct quote and provide the corresponding reference citation if it is.
Q11	Please verify the term "progressors."
Q12	Please verify the term "necroinflammatory."
Q13	Please verify that the addition of the term "prevalence" preserves your intent in the sentence beginning "This prevalence is an"
Q14	Please note that, per Clinics style, the term <i>case</i> refers to the instance of a disease and not a person. Please verify that the use of the term <i>case</i> in the article reflects Clinics style.
Q15	Please verify the third editor name in Ref. 4.
Q16	Symbol "*" that was cited in certain references has been removed. Please verify.
Q17	Reference citations were not in sequential order. Hence, Refs. 6–22, 31–41 have been renumbered both in text and in reference list. Please verify.
Q18	ALT is expanded in the original manuscript's abbreviation list as "alanine transaminase" but as "alanine aminotransferase" in the Table 1 abbreviation list. Please clarify which is expansion is correct.

Thank you for your assistance.